tradingkey.logo
tradingkey.logo
Search

HK Movers | JD Health Jumps Over 6% as Q3 Operating Profit Increases More Than 1.25 Times YoY

TigerNov 14, 2025 2:30 AM
facebooktwitterlinkedin
View all comments(0)

JD Health stocks jumped more than 6% in Hong Kong. Its third-quarter operating profit increased over 1.25 times year-on-year, alongside establishing strategic collaborations with several renowned pharmaceutical companies.

On November 13, JD Health announced its third-quarter results for 2025. The group achieved revenue of RMB 17.12 billion, a year-on-year increase of 28.7%, and an operating profit of RMB 1.243 billion, up 125.3% compared to the previous year.

In the third quarter of 2025, JD Health signed strategic cooperation agreements with prominent pharmaceutical companies such as Lilly (LLY), Innovent Biologics (01801), Eisai China, and Bayer China. New drugs, including Eisai's original innovative medication, Dayvigo® (lemborexant tablets), Hengrui’s new dry eye drug Hengqin® (perfluorohexyloctane eye drops), and Bayer’s Daxalt® lactulose were launched on JD Health's platform, reinforcing JD Health's position as the leading station for exclusive new drug releases. Beyond pharmaceuticals, new health products such as Centrum Silver® unveiled by Haleon and the first domestic formula medical food for phenylketonuria, Special Love Benjia, launched by Sheng Tong Medical Nutrition were all available for launch on JD Health's comprehensive platform.

In September 2025, JD Health completed a collaboration agreement with Huazhong University of Science and Technology's Tongji Medical College Affiliated Union Hospital, aspiring to build a nationally leading smart outpatient patient service platform. The collaboration will advance the application of JD Zhuoyi AI products in hospital outpatient service scenarios, establishing a full-process AI-assisted system to offer patients a more convenient medical experience. They will also deepen cooperation in remote medical services, jointly exploring new models of "Internet + Medical Health" services.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.